Trending...
- InventHelp Inventor Develops a Communication Device to Assist Patients and Medical Professionals (PLB-169)
- Essential Properties Realty Trust, Inc. Announces Pricing of Upsized Primary Public Offering of Common Stock
- CME Webinar- Best Practices for the Management of Individuals with #Cushings Disease
MONMOUTH JUNCTION, N.J. - JerseyDesk -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation technology for studying malignant ascites in peritoneal metastases of epithelial ovarian cancer. The citation is:
Yang, X. U. A. N., et al. "SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells (https://assets.researchsquare.com/files/rs-1087...)." (2021).
Malignant ascites in peritoneal metastases is a lipid-enriched microenvironment and is frequently involved in the poor prognosis of epithelial ovarian cancer (EOC). However, the detailed mechanisms underlying ovarian cancer (OvCa) cells dictating their lipid metabolic activities in promoting tumor progression remain elusive.
For this, the BSG product Cleanascite™ was used as a lipid-cleared control in the investigation. The article states: "Compared with the negative controls (OCM pretreated with the lipid removal reagent, Cleanascite), OvCa cells cocultured in the lipid-enriched OCM showed an increase of 18% in membrane fluidity." The authors describe a disruption of the cellular redox balance and subsequent iron-mediated lipid peroxidation in ascites-derived OvCa cells. They conclude that combinational treatment with SCD1/FADS2 inhibitors and cisplatin synergistically repressed tumor cell dissemination, providing a promising chemotherapeutic strategy against EOC platinum resistance and peritoneal metastases.
More on Jersey Desk
"We have over twenty references showing that Cleanascite™ was used to help identify a characteristic feature of in vitro cell response. Unlike methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations to determine whether or not lipids, or factors associated with lipids, impart phenotypic changes to cells." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
To download whitepaper entitled "Cleanascite™ - Lipid Removal and Cell Response Applications", visit:
https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications113021.pdf
For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
About Biotech Support Group LLC
Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include:biotechsupportgroup AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.
More on Jersey Desk
For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com (mailto:sales@biotechsupportgroup.com)
Yang, X. U. A. N., et al. "SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells (https://assets.researchsquare.com/files/rs-1087...)." (2021).
Malignant ascites in peritoneal metastases is a lipid-enriched microenvironment and is frequently involved in the poor prognosis of epithelial ovarian cancer (EOC). However, the detailed mechanisms underlying ovarian cancer (OvCa) cells dictating their lipid metabolic activities in promoting tumor progression remain elusive.
For this, the BSG product Cleanascite™ was used as a lipid-cleared control in the investigation. The article states: "Compared with the negative controls (OCM pretreated with the lipid removal reagent, Cleanascite), OvCa cells cocultured in the lipid-enriched OCM showed an increase of 18% in membrane fluidity." The authors describe a disruption of the cellular redox balance and subsequent iron-mediated lipid peroxidation in ascites-derived OvCa cells. They conclude that combinational treatment with SCD1/FADS2 inhibitors and cisplatin synergistically repressed tumor cell dissemination, providing a promising chemotherapeutic strategy against EOC platinum resistance and peritoneal metastases.
More on Jersey Desk
- Kinugawa Onsen Celebrates its 330th Anniversary AND Kawagoe City Celebrates its 100th Anniversary - Both with Fireworks!
- Rook Coffee Brings A Fresh Favorite Back
- Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
- VA Center of North County Hosts It's First Annual VANC Fest; an Art, Music and Culinary Experience
- 10 Years in the Making: #LatinaGeeks Celebrates 10th Anniversary with Inaugural Inspirada Awards & Fundraising Gala
"We have over twenty references showing that Cleanascite™ was used to help identify a characteristic feature of in vitro cell response. Unlike methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations to determine whether or not lipids, or factors associated with lipids, impart phenotypic changes to cells." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
To download whitepaper entitled "Cleanascite™ - Lipid Removal and Cell Response Applications", visit:
https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications113021.pdf
For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
About Biotech Support Group LLC
Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include:biotechsupportgroup AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.
More on Jersey Desk
- CME Symposium- Fine-Tuning the Management of Patients with #WorseningHeartFailure with Reduced Ejection Fraction
- Alacriti Appoints New Chief Sales Officer and SVP of Faster Payments
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- Cross River Doubles Down on Community Commitment with Spotlight on Financial Literacy
- Perle wins Network Management Product of the Year
For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com (mailto:sales@biotechsupportgroup.com)
Source: Biotech Support Group
0 Comments
Latest on Jersey Desk
- Beyond Visionary Has Partnered With Heal America To Host INFORM Dallas
- Nominations Now Open for Prestigious NJTIA Tourism Excellence Awards
- What You Need to Know on "Opening an IV Therapy Clinic" Podcast Interview to Grow, Start or Expand IV Hydration Therapy Business
- Group for LGBTQ+ Adults with Developmental Disabilities to Hold Virtual Meeting on August 16, 7pm
- New True Powerhouse Partners Bring Talent Acquisition, DE&I and HR Expertise
- Century 21's The Gene Group Joins PalMar Studios as a Primary Partner on "Triangle Park," a Documentary on the NFL's First-Ever Game
- Essential Properties Realty Trust, Inc. Announces Pricing of Upsized Primary Public Offering of Common Stock
- B&G Foods Declares Regular Quarterly Dividend
- Prince Oak Oakleyski has finished directing and already released his new film, the final episode of "Prince Oakleyski Is Enough". A non-profit movie
- 3C Group to Distribute Certified Nutraceuticals' Functional Ingredients for Dietary Supplements in Thailand
- American Water Achieves Drone Program Milestone, Earns FAA BVLOS Waiver
- Calling All Witches: WitchFest 2022 Announced in Denver Colorado
- InventHelp Inventor Develops a Communication Device to Assist Patients and Medical Professionals (PLB-169)
- Extremity Medical Receives Vizient Small Joints National Contract
- B&G Foods Announces Date of Second Quarter 2022 Earnings Conference Call
- New music from Sho Richardsin, 'The Win'
- Bridgepointe Condominiums Picks Corner Property To Manage Modern Development In Laurence Harbor NJ
- AB Value-Radoff Group Announces Acceptance of Latest Settlement Terms Proposed by Rocky Mountain Chocolate Factory
- Carluccio, Leone, Dimon, Doyle & Sacks, LLC welcomes Michael Nolan as Senior Litigation Attorney
- Sharifah Hardie Launches Campaign to Raise $1.5B for Local Black Businesses